Pharma Intelligence is part of the Business Intelligence Division of Informa PLC
TThis is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Orphan drugs have gained increased attention in recent years from patients, drug developers, and investors. However, developing therapeutic options for patients affected by rare genetic diseases is challenging, and incorporating additional dimensions of understanding the disease beyond genotype and phenotype is critical for success.
If you are tackling the challenges of orphan drugs in early stage development, clinical trial enrollment, or market development, listen now to learn more about How Multiomics and Biomarkers in Rare Diseases are Supporting Development and Commercialization of Orphan Drugs.
Questions addressed during the webinar:
CENTOGENE is dedicated to transforming the science of genetic information into solutions. We’re using our unique platform composed of a global database, biobank, and analytical tools to accelerate preclinical, clinical, and commercial programs in support of curing genetic disorders.
Listen now as we fight to improve outcomes for patients and their families.
Chief Business Officer, CENTOGENE
Oved serves as Chief Business Officer with nearly three decades of broad commercial and development experience, focusing on orphan drugs for patients with rare genetic diseases. He has the overall responsibility for the company´s pharmaceutical industry programs, including enhancing existing partnerships and establishing new collaborations to facilitate drug development and improve treatment outcomes.
Oved joined CENTOGENE from Arrett Neuroscience where he held the position of President and Chief Operating Officer, having led the company’s strategy for developing therapies for Rett syndrome. Prior to that, he served as Vice President, Head of Commercial at Alnylam Pharmaceuticals, with a lead role in the organization’s transition from a technology- platform focus to a patient-centric drug development and pre-launch enterprise. Oved had a long tenure at Genzyme Corporation (now Sanofi Genzyme) as Vice President, Strategic Development, responsible for program management, business development, market assessment, and business planning for the rare genetic diseases franchise, and as General Manager of the Gaucher and MPS business. He is also a Founding Advisor of Splisense Therapeutics, Israel. Oved holds a M.Sc., Pharmacology, from Northeastern University, Boston, MA and a B.Sc., Pharmacy, from the Hebrew University, Jerusalem, Israel.
Vice President Business Development, CENTOGENE
Justin, as Senior Vice President of Business Development, leads a global team developing our pharmaceutical partnership strategy with the goal of maximizing value through accelerating and de-risking orphan drug programs for rare genetic diseases.
Prior to CENTOGENE, Justin was the Director of Business Development at Synthetic Genomics, Inc (SGI) and responsible for pharma and life science partnerships and collaborations. Justin also led the global marketing and sales activities for SGI-DNA, Inc., a wholly owned subsidiary of SGI and life sciences company developing synthetic biology tools and technologies with global applications. He draws from more than 10 years as a cell biologist working in preclinical drug discovery first with the Genomics Institute of the Novartis Research Foundation (GNF) and then the Exploratory Technologies Group within Pfizer Research and Development.
His broad experience as a scientist and in scaling life science and biotechnology companies to meet the demands of their partners provides a unique perspective and helps CENTOGENE to build value as a company.
Chief Genomic Officer, CENTOGENE
Peter serves as CGO, combining clinical and medical understanding in genetic testing with an excellent knowledge of the latest scientific developments, based on his extraordinary experience, especially in high-throughput genetic testing using next-generation sequencing.
Peter is passionate about turning medical questions into a complete and fast analytical process, ensuring that the medically driven result is brought back to the clinician and the patient immediately.
After studying Medicine in Freiburg and Berlin, Peter worked as a resident in Neurology at Rostock, and as a resident in Human Genetics at Tübingen since 1997. He received his board certification in Human Genetics in 2006, and heads the molecular diagnostic laboratory at the Institute of Medical Genetics and Applied Genomics at the University Hospital Tübingen. His experience ranges from medium- to high-throughput genetic analyses, including the application of next-generation sequencing in a clinical setting, genetic research in neurodegenerative disease and hereditary cancer. Peter has an extensive track record in medical and scientific publications, focusing on neurogenetics, oncogenetics, cardiogenetics, and sequencing technology. He is co-principal investigator in a large European consortium on rare neurodegenerative diseases, where he overlooks specifically gene panel, exome and genome sequencing (www.rd-neuromics.eu). Moreover, Peter is vice president of the German Society of Neurogenetics (DGNG).
Editor, Custom Content
Informa Pharma Intelligence